Synthesis of 3-(α-Chlorophenylhydrazono)heteroarylmethyl-2-oxo-1,2-dihydroquinoxalines with Antimicrobial Activity [1]

Yoshihisa Kurasawa*, Muneto Muramatsu, Kaoru Yamazaki,

Yoshihisa Okamoto and Atsushi Takada

School of Pharmaceutical Sciences, Kitasato University, Shirokane, Minato-ku, Tokyo 108, Japan Received January 6, 1986

J. Heterocyclic Chem., 23, 1387 (1986).

In previous papers, we reported the synthesis of various oxadiazoles [2-4] and triazoles [5-7] from the interest in their pharmacological activities as the bactericidal, fungicidal and herbicidal agents [3a,5a]. The azoles synthesized so far by us include the quinoxaline moiety in their molecules, and some of the representative compounds shown in Chart 1 have been found to exhibit the antifungal activity

Chart 1

against Pathium debaryanum, Pyriclaria oryzae and Rhizoctonia solani in 11-39%, 17-61% and 40-74% growth inhibition, respectively, at a concentration of 100 ppm [8]. In continuation of the above works, we synthesized 1-aryl-3-quinoxalinyl-1,2,4-triazoles **1a-c** from the ester **2** via the α -hydrazonoesters **3a-c** and α -hydrazonoacylhydrazides **4a-c** [9] (Chart 2) to carry out the screening test. As the

result, the 1-aryl-3-quinoxalinyl-1,2,4-triazoles $\bf 1a-c$ did not show any growth inhibition activity against the above three kinds of fungi, but, unexpectedly, the α -hydrazonoesters $\bf 3a-c$ were found to represent the 60-100% growth inhibition activity against Pythium debaryanum at a concentration of 100 ppm. These results suggested that the analogue of the α -hydrazono compounds $\bf 3a-c$ would also have the antifungal activity. Accordingly, we undertook the conversion of the ester group of $\bf 3$ into the heterocyclic moiety in order to search for the other fungicidal agents. This paper describes the synthesis of $\bf 3-(\alpha$ -chlorophenyl-hydrazono)heteroarylmethyl-2-oxo-1,2-dihydroquinoxalines $\bf 5a-d$ and $\bf 9a-c$ and their antimicrobial activities.

R=CONHNH2

4 a-c

Synthesis of 3-(α-Chlorophenylhydrazono-1,3,4-oxadiazol-2-ylmethyl)-2-oxo-1,2-dihydroquinoxalines **5a-d**.

The α -hydrazonoacylhydrazides **4a**,**c** are selected as

starting materials for the purpose of the construction of an additional heterocyclic ring in the molecule, since the acyl hydrazide moiety has been easily converted into the oxadiazole ring [3,10,11].

The reactions of 4a,c with triethyl orthoesters (R = H, Me) would afford intermediates Ia-d [3] (Scheme 1), whose subsequent cyclizations provided a sole product. The pmr spectral data of these cyclization products in deuteriodimethylsulfoxide supported the structures of the 3-(α -chlorophenylhydrazono-1,3,4-oxadiazol-2-ylmethyl)-2-oxo-1,2dihydroquinoxalines 5a-d, but not the 1,2,4,5-tetrazepinylquinoxalines 6a-d. Namely, the spectra of 5a-d exhibited the tautomeric equilibria between the hydrazone imine form A and the diazenyl enamine form B (Scheme 2) [12]. The hydrazone NH (due to the A form) and N4-H (due to the B form) proton signals were observed in the spectra of 5a-d [12]. In addition, the two C₅-H proton signals due to the A and B forms were observed in the respective spectra of 5a,b, while the two C5-Me carbon signals due to the A and B forms were observed in the ¹³C-nmr spectra of 5c (δ 10.67, 10.48 ppm) and **5d** (δ 10.71, 10.51 ppm) [12].

The above cyclization mode of $\mathbf{4a}$, \mathbf{c} into the oxadiazole ring were ascertained by the following alternate syntheses. The reactions of 3-(1,3,4-oxadiazol-2-ylmethylene)-2-oxol,2,3,4-tetrahydroquinoxalines $\mathbf{7a}$, \mathbf{b} ($\mathbf{R} = \mathbf{H}$, \mathbf{Me}) [3] with o-chlorobenzenediazonium chloride resulted in the diazotization at the methylenic carbon [9] to furnish $\mathbf{5a}$, \mathbf{c} .

Thus, the above spectral data and alternate syntheses enabled us to deny the cyclization manner of **Ia-d** into the 1,2,4,5-tetrazepinylquinoxalines **6a-d**.

Scheme 2

Synthesis of 3-(α-Chlorophenylhydrazonobenzimidazol-2-ylmethyl)-2-oxo-1,2-dihydroquinoxaline Hydrochlorides 9a-c.

Since the above alternate syntheses of 5a,c from 7a,b supplied a convenient method for the syntheses of the $3-(\alpha-chlorophenylhydrazono)heteroarylmethyl-2-oxo-1,2-dihydroquinoxalines, this method was utilized as follows.$

The reactions of 3-(benzimidazol-2-ylmethylene)-2-oxo-1,2,3,4-tetrahydroquinoxaline hydrochloride $\bf 8$ [13] with o-, m- and p-chlorobenzenediazonium chlorides effected the diazotization at the methylenic carbon to give the 3-(α -chlorophenylhydrazonobenzimidazol-2-ylmethyl)-2-oxo-1,2-dihydroquinoxaline hydrochlorides $\bf 9a$ -c, respectively. The pmr spectra of $\bf 9a$ -c were measured in trifluoroacetic acid because of their insolubility in most of the solvents, and hence the tautomeric equilibria between the $\bf A$ and $\bf B$ forms (Scheme 2) could not be examined in $\bf 9a$ -c.

Antifungal and Antibacterial Activities.

Compounds 5a-d exhibited the weak antifungal activity

Scheme 3

(11-33% growth inhibition) against Pathium debaryanum, Pyriclaria oryzae and Rhizoctonia solani at the concentrations of 10 and 100 ppm, while 5b,d (p-chloro series) showed the antibacterial activity (100% growth inhibition) against Xanthomonas oryzae at 100 ppm. On the other hand, 9a-c represented the antifungal activity (68-88% growth inhibition) against Pathium debaryanum at 100 ppm, whereas the weak antifungal activity (6-36% growth inhibition) was shown against Pyriclaria oryzae and Rhizoctonia solani at 50 and 100 ppm.

EXPERIMENTAL

All melting points were determined on an Ishii melting point apparatus and are uncorrected. Infrared (ir) spectra were recorded from potassium bromide discs on a JASCO IRA-1 spectrophotometer (JEOL). The pmr spectra were measured with an EM 390 spectrometer at 90 MHz, using tetramethylsilane as an internal standard. Chemical shifts are given in a δ scale relative to the internal standard. The mass spectra (ms) were determined with a JEOL JMS-01S spectrometer.

 $3-(\alpha-Chlorophenylhydrazono-1,3,4-oxadiazol-2-ylmethyl)-2-oxo-1,2-dihydroquinoxalines 5a,b.$

A solution of **4a** or **4c** (10 g) and triethyl orthoformate (100 ml) in acetic acid (500 ml) was refluxed in an oil bath for 5 hours to precipitate crystals, which were excluded by suction filtration. Evaporation of the filtrate in vacuo afforded yellow crystals **5** [a, 5.17 g (55%), b, 5.94 g (63%)]. Recrystallization from N,N-dimethylformamide/ethanol provided yellow needles, mp 281-282° (**5a**), 270-271° (**5b**); ms: m/z 366 (M*), 368 (M*+2) (**5a**,b); ir: ν cm⁻¹ 1660, 1607, 1590, 1570 (**5a**), 1670, 1605, 1590 (**5b**); pmr (deuteriodimethylsulfoxide): 14.35 (s, 2/3 H, = N-NH-) [12], 12.80 (s, 1H, N₁-H), 12.45 (s, 1/3 H, N₄-H) [12], 9.47 (s, 1/3 H, C₅-H) [12], 8.03-6.80 (m, 8H, aromatic) (**5a**); 12.80 (s, 1H, N₁-H), 11.97 (s, 1/6 H, N₄-H) [12], 11.45 (s, 5/6 H, = N-NH-) [12], 9.42 (s, 1/6 H, C₅-H [12], 9.27 (s, 5/6 H, C₅-H) [12], 8.07-7.10 (m, 8H, aromatic), (**5b**).

Anal. Caled. for $C_{17}H_{11}CIN_{\alpha}O_{2}$: C, 55.67; H, 3.02; Cl, 9.67; N, 22.91. Found: C, 55.45; H, 3.06; Cl, 9.65; N, 23.06 (5a); C, 55.48; H, 3.11; Cl, 9.41; N, 22.67 (5b).

 $3-(\alpha-Chlorophenylhydrazono-5-methyl-1,3,4-oxadiazol-2-ylmethyl)-2-oxo-1,2-dihydroquinoxalines <math>\mathbf{5c}$, \mathbf{d} .

A solution of 4a or 4c (10 g) and triethyl orthoacetate (100 ml) in acetic acid (500 ml) was refluxed in an oil bath for 5 hours. Evaporation of the solvent in vacuo furnished yellow crystals 5 [c, 7.10 g (73%), d 8.28 g (78%)]. Recrystallization from N,N-dimethylformamide/ethanol gave yellow needles, mp 276-277° (5c), 267-268° (5d); ms: m/z 380 (M*), 382 (M*+2) (5c,d); ir: ν cm⁻¹ 1670, 1607, 1590, 1570 (5c), 1660, 1605, 1590,

1565 (**5d**); pmr (deuteriodimethylsulfoxide): 14.22 (s, 1/2 H, = N-NH-) [12], 12.77 (s, 1H, N_1 -H), 12.42 (s, 1/2 H, N_4 -H) [12], 8.00-6.93 (m, 8H, aromatic), 2.57 (s, 3H, C_5 -Me) (**5c**); 12.76 (s, 1H, N_1 -H), 11.95 (s, 1/5 H, N_4 -H) [12], 11.18 (s, 4/5 H, = N-NH-) [12], 8.07-7.17 (m, 8H, aromatic), 2.59 (s, 3H, Me) (**5d**).

Anal. Calcd. for $C_{10}H_{13}CIN_6O_2$: C, 56.78; H, 3.44; Cl, 9.31; N, 22.07. Found: C, 56.55; H, 3.44; Cl, 9.16; N, 22.28 (5c); C, 56.52; H, 3.50; Cl, 9.23; N, 22.14 (5d).

Alternate Syntheses of 5a,c.

A solution of sodium nitrite (0.364 g, 5.27 mmoles) in water (10 ml) was added dropwise to a suspension of o-chloroaniline hydrochloride (0.864 g, 5.27 mmoles) in acetic acid (20 ml) with stirring in an ice-water bath to give a clear solution, which was added to a suspension of 7a (1 g, 4.93 mmoles) in acetic acid (30 ml) and water (10 ml) with stirring in an ice-water bath. After stirring was continued for 30 minutes, the reaction mixture was heated on a boiling water bath for 1 hour with an initial stirring to afford a clear solution and then to precipitate yellow crystals 5a, which were collected by suction filtration (0.64 g). Evaporation of the filtrate in vacuo afforded yellow crystals 5a (0.50 g). Total yield, 1.14 g (71%).

Compound **5c** was obtained by a similar manner to the above (73%). 3-(α-Chlorophenylhydrazonobenzimidazol-2-ylmethyl)-2-oxo-1,2-dihydroquinoxalines **9a-c**.

A solution of sodium nitrite (0.53 g, 7.68 mmoles) in water (20 ml) was added dropwise to a suspension of the appropriate chloroaniline hydrochloride (1.26 g, 7.68 mmoles) in 5% hydrochloric acid (20 ml) with stirring in an ice-water bath to give a clear solution, which was added to a suspension of **8** (2.0 g, 6.40 mmoles) in acetic acid (30 ml) and water (30 ml) with stirring in an ice-water bath. After stirring was continued for 10 minutes, the reaction mixture was heated on a boiling water bath for 1 hour with an initial stirring to give yellow needles **9**, which were collected by suction filtration [a, 2.60 g (98%), b, 2.65 g (100%), c, 2.66 g (100%)]. Trituration with hot N_iN -dimethylformamide afforded analytically pure yellow needles, mp, 301-302° (9a), 299-300° (9b), 291-292° (9c); ms: m/z 414 (M*), 416 (M* + 2) (9a-c); ir: ν cm⁻¹ 1680 (9a), 1665 (9b), 1665 (9c); pmr (trifluoroacetic acid): 8.33-6.90 (m, aromatic) (9b), 8.33-6.90 (m, aromatic) (9c). The NH proton signals were unobservable.

Anal. Calcd. for $C_{22}H_{16}Cl_2N_6O$: C, 58.55; H, 3.57; Cl, 15.71; N, 18.62. Found: C, 58.78; H, 3.59; Cl, 15.58; N, 18.44 (9a); C, 58.58; H, 3.46; Cl, 15.44; N, 18.52 (9b); C, 58.72; H, 3.50; Cl, 15.45; N, 18.41 (9c).

Table

Antifungal and Antibacterial Activities of Compounds 5a-d and 9a-c

Compound	Concentration (ppm)	Activity [a]			
		P.d.	P.o.	R.s.	X.o. [b]
5a	100	14	29	27	
	10	12	12	14	
5b	100	21	2	24	100
	10	14	2	10	
5e	100	30	62	27	
	10	11	0	13	
5d	100	19	28	33	100
	10	11	9	27	
9 a	100	68	22	67	
	50	46	21	6	
9b	100	78	24	27	
	50	50	23	16	
9c	100	88	35	36	
, C	50	49	29	10	

[a] Growth inhibition (%). [b] P.d.: Pythium debaryanum; P.o.: Pyriclaria oryzae; R.s.: Rhizoctonia solani; X.o.: Xanthomonas oryzae.

- [9] Y. Kurasawa, M. Muramatsu, K. Hotehama, Y. Okamot and A. Takada, J. Heterocyclic Chem., 22, 1711 (1985); 4a was obtained as the hydrazinium salt, and 4c as the free base.
 - [10] C. A. Ainsworth, J. Am. Chem. Soc., 77, 1148 (1955).
- [11] Y. Kurasawa, M. Muramatsu, K. Yamazaki, S. Tajima, Y. Okamoto and A. Takada, J. Heterocyclic Chem., 23, 633 (1986).
- [12] Y. Kurasawa, M. Muramatsu, K. Yamazaki, S. Tajima, Y. Okamoto and A. Takada, J. Heterocyclic Chem., in press.
- The tautomer ratios of the **A** form versus the **B** form are as follows; 2:1 (5a), 5:1 (5b), 1:1 (5c), 4:1 (5d).
- [13] Y. Kurasawa, S. Shimabukuro, Y. Okamoto and A. Takada, J. Heterocyclic Chem., 22, 1461 (1985).

Acknowledgement.

We wish to thank Nissan Chemical Industries, Ltd., (Chiba Prefecture, Japan) for the antifungal and antibacterial screening tests.

REFERENCES AND NOTES

- [1] Preliminary report: Y. Kurasawa, M. Muramatsu, Y. Okamoto and A. Takada, J. Heterocyclic Chem., 23, 637 (1986).
- [2] Y. Kurasawa, M. Ichikawa, A. Sakakura and A. Takada, Chem. Pharm. Bull., 32, 4140 (1984).
- [3a] Y. Kurasawa, Y. Moritaki and A. Takada, Synthesis, 328 (1983); [b]Y. Kurasawa, Y. Moritaki, T. Ebukuro and A. Takada, Chem. Pharm. Bull., 31, 3897 (1983).
- [4] Y. Kurasawa, S. Nakamura, K. Moriyama, K. Suzuki and A. Takada, Heterocycles, 22, 1189 (1984).
- [5a] Y. Kurasawa, K. Suzuki, S. Nakamura, K. Moriyama and A. Takada, *Heterocycles*, **22**, 695 (1984); [b] *Idem, Chem. Pharm. Bull.*, **32**, 4752 (1984).
- [6] Y. Kurasawa, M. Ichikawa, I. Kamata, Y. Okamoto and A. Takada, *Heterocycles*, 23, 281 (1985); Y. Kurasawa, Y. Okamoto and A. Takada, *J. Heterocyclic Chem.*, 22, 1715 (1985).
- [7] Y. Kurasawa, Y. Okamoto and A. Takada, J. Heterocyclic Chem., 22, 935 (1985).
 - [8] These screening data have not been reported previously.